What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
Yelena Janjigian, MD
PeerWhat Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
Samuel J. Klempner, MD
PeerWhat Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
Yelena Janjigian, MD
PeerYelena Janjigian, MD
PeerClaudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
PeerKris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
PeerWalk a Mile in My Shoes
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Peer